177 related articles for article (PubMed ID: 11337555)
1. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line.
Lorke DE; Krüger M; Buchert R; Bohuslavizki KH; Clausen M; Schumacher U
J Nucl Med; 2001 Apr; 42(4):646-54. PubMed ID: 11337555
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the relationship between [18F]FDG and P-glycoprotein expression: an experimental study.
Yu C; Wan W; Zhang B; Deng S; Yen TC; Wu Y
Nucl Med Biol; 2012 Jul; 39(5):671-8. PubMed ID: 22264856
[TBL] [Abstract][Full Text] [Related]
4. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.
Moretti JL; Duran Cordobes M; Starzec A; de Beco V; Vergote J; Benazzouz F; Boissier B; Cohen H; Safi N; Piperno-Neumann S; Kouyoumdjian JC
J Nucl Med; 1998 Jul; 39(7):1214-8. PubMed ID: 9669397
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with (99m)Tc-sestamibi, (201)Tl chloride and (99m)Tc-HL91.
Kinuya S; Yokoyama K; Li XF; Bai J; Watanabe N; Shuke N; Takayama T; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1006-11. PubMed ID: 12173013
[TBL] [Abstract][Full Text] [Related]
6. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
[TBL] [Abstract][Full Text] [Related]
7. Different Efflux Transporter Affinity and Metabolism of
Kobayashi M; Tsujiuchi T; Okui Y; Mizutani A; Nishi K; Nakanishi T; Nishii R; Fukuchi K; Tamai I; Kawai K
Pharm Res; 2018 Nov; 36(1):18. PubMed ID: 30498970
[TBL] [Abstract][Full Text] [Related]
8. (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.
Sasajima T; Shimada N; Naitoh Y; Takahashi M; Hu Y; Satoh T; Mizoi K
Int J Cancer; 2007 Dec; 121(12):2637-45. PubMed ID: 17708555
[TBL] [Abstract][Full Text] [Related]
9. Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.
Liu Z; Stevenson GD; Barrett HH; Furenlid LR; Wilson DW; Kastis GA; Bettan M; Woolfenden JM
Nucl Med Biol; 2005 Aug; 32(6):573-83. PubMed ID: 16026704
[TBL] [Abstract][Full Text] [Related]
10. Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2-deoxy-D-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells.
Márián T; Balkay L; Trón L; Krasznai ZT; Szabó-Péli J; Krasznai Z
Eur J Pharm Sci; 2005 Apr; 24(5):495-501. PubMed ID: 15784339
[TBL] [Abstract][Full Text] [Related]
11. Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study.
Kurata S; Ushijima K; Kawahara A; Kaida H; Kawano K; Hirose Y; Kage M; Kamura T; Ishibashi M; Abe T
Ann Nucl Med; 2015 Aug; 29(7):643-9. PubMed ID: 25921216
[TBL] [Abstract][Full Text] [Related]
12. Biphasic accumulation kinetics of [99mTc]-hexakis-2-methoxyisobutyl isonitrile in tumour cells and its modulation by lipophilic P-glycoprotein ligands.
Márián T; Balkay L; Szabó G; Krasznai ZT; Hernádi Z; Galuska L; Szabó-Péli J; Esik O; Trón L; Krasznai Z
Eur J Pharm Sci; 2005 Jun; 25(2-3):201-9. PubMed ID: 15911215
[TBL] [Abstract][Full Text] [Related]
13. Human sodium iodide symporter added to multidrug resistance 1 small hairpin RNA in a single gene construct enhances the therapeutic effects of radioiodine in a nude mouse model of multidrug resistant colon cancer.
Jeon YH; Ahn SJ; Lee YJ; Lee YL; Lee SW; Park SY; Kim IS; Ahn BC; Ha JH; Lee J
Cancer Biother Radiopharm; 2010 Dec; 25(6):671-9. PubMed ID: 21204761
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
15. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response.
Burak Z; Ersoy O; Moretti JL; Erinç R; Ozcan Z; Dirlik A; Sabah D; Basdemir G
Eur J Nucl Med; 2001 Sep; 28(9):1341-50. PubMed ID: 11585293
[TBL] [Abstract][Full Text] [Related]
16. 99mTc glucarate high-resolution imaging of drug sensitive and drug resistant human breast cancer xenografts in SCID mice.
Liu Z; Stevenson GD; Barrett HH; Kastis GA; Bettan M; Furenlid LR; Wilson DW; Woolfenden JM; Pak KY
Nucl Med Commun; 2004 Jul; 25(7):711-20. PubMed ID: 15208499
[TBL] [Abstract][Full Text] [Related]
17. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
Burak Z; Moretti JL; Ersoy O; Sanli U; Kantar M; Tamgac F; Basdemir G
J Nucl Med; 2003 Sep; 44(9):1394-401. PubMed ID: 12960182
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intratumoral distribution of 99mTc-MIBI and deoxyglucose in mouse breast cancer models.
Ohira H; Kubota K; Ohuchi N; Harada Y; Fukuda H; Satomi S
J Nucl Med; 2000 Sep; 41(9):1561-8. PubMed ID: 10994739
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging.
Tatsumi M; Tsuruo T; Nishimura T
Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):288-94. PubMed ID: 12002701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
